Leading small business
innovation and commercialization
in the fight against cancer
The SBIR & STTR Programs are one of the largest sources of early stage technology financing in the United States. We welcome entrepreneurs and small business leaders to this website to explore grant and contract funding opportunities.
Learn how NCI SBIR & STTR Programs have helped small businesses with funding awards that help advance cancer research.
NovaRx, a biopharmaceutical company based in San Diego, has used SBIR funding since 2002 to successfully transition its vaccine platform technology from early research in immunogenicity to clinical trials that have shown promising results in non-small-cell lung cancer and other disease areas.
Naviscan, a medical device company based in San Diego, used Phase I and II SBIR funding to bring improved breast cancer imaging technology through the stages of prototype building, clinical trials, and definitive post-marketing trials. The PEM Flex® PET Scanner now allows physicians to visualize breast tumors about the size of a grain of rice.
Awarded more than $4 million to develop a technology platform of safe and effective carriers for therapeutic vaccines based on hemocyanin from the keyhole limpet (KLH) protein.
GRANT DEADLINE APPROACHING: SEPTEMBER 8, 2015 (September 5 is a weekend and September 7 is a Federal Holiday) for SBIR & STTR Omnibus Solicitations (Phase I, Phase II, Fast Track, and Direct to Phase II), plus "Single Cell" PA-13-140.
Applying to the FY2016 Contract Solicitation? Check out these webinar materials for helpful information and tips.
The NCI SBIR Program released 14 new opportunities and has a new electronic submissions process. The deadline to apply for FY2016 contract topics is October 16, 2015 by 5:00 PM EDT
The NIH SBIR/STTR CAP is now accepting apps from Phase II awardees. The deadline for submitting an application is September 11, 2015. http://1.usa.gov/1J93fg2
Download slides from a webinar about the I-Corps™ at NIH pilot program, which seeks to accelerate development and commercialization of new SBIR/STTR-funded products and services.
This site is undergoing remediation for compliance with Section 508. The remediation will be complete by July 31, 2015.
In the interim, should you require any accessibility assistance with any content, please contact NCI SBIR & STTR